OliX Pharmaceuticals Valuation

Is A226950 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A226950 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A226950's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A226950's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A226950?

Key metric: As A226950 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A226950. This is calculated by dividing A226950's market cap by their current revenue.
What is A226950's PS Ratio?
PS Ratio	20.1x
Sales	₩17.90b
Market Cap	₩363.73b

A226950 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	21.7x
Enterprise Value/EBITDA	-27.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A226950's PS Ratio compare to its peers?

The above table shows the PS ratio for A226950 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.5x
A290650 L&C BIOLTD	5.4x	n/a	₩390.4b
A206650 EuBiologics	6.8x	21.9%	₩470.6b
A304360 S.Biomedics	18.9x	n/a	₩245.5b
A086890 ISU Abxis	2.9x	n/a	₩179.9b
A226950 OliX Pharmaceuticals	20.1x	n/a	₩360.3b

Price-To-Sales vs Peers: A226950 is expensive based on its Price-To-Sales Ratio (20.1x) compared to the peer average (8.5x).

Price to Sales Ratio vs Industry

How does A226950's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	1x	9.0%	US$1.22b
A096530 Seegene	2.8x	15.7%	US$790.79m
A086900 Medy-Tox	3.7x	14.5%	US$641.97m
A005250 Green Cross Holdings	0.3x	n/a	US$498.99m

26 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A226950 is expensive based on its Price-To-Sales Ratio (20.1x) compared to the KR Biotechs industry average (9x).

Price to Sales Ratio vs Fair Ratio

What is A226950's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A226950 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	20.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A226950's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

6.0%

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

-3.4%

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

-2.0%

8.6%